ChiCTR2600123197 版本V1.1 版本创建时间2026/04/29 15:52:35 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123197 

最近更新日期:

Date of Last Refreshed on:

2026-04-22 16:10:34 

注册时间:

Date of Registration:

2026-04-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

全腹腔镜下全肝肝移植的临床疗效分析

Public title:

Clinical efficacy analysis of total laparoscopic liver transplantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

全腹腔镜下全肝肝移植的临床疗效分析

Scientific title:

Clinical efficacy analysis of total laparoscopic liver transplantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙强 

研究负责人:

孙强 

Applicant:

Sun Qiang 

Study leader:

Sun Qiang 

申请注册联系人电话:

Applicant telephone:

+86 760 89880326

研究负责人电话:

Study leader's
telephone:

+86 760 8988 0300

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sqchina@163.com

研究负责人电子邮件:

Study leader's E-mail:

sqchina@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省中山市石岐街道孙文东路2号

研究负责人通讯地址:

中山市石岐区孙文东路2号

Applicant address:

No. 2 Sun Wenden Road, Shiqi Subdistrict, Zhongshan City, Guangdong Province

Study leader's address:

No.2 Sunwen East Road,Zhongshan City, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山市人民医院

Applicant's institution:

Zhongshan city People's Hospital

研究负责人所在单位:

中山市人民医院

Affiliation of the Leader:

Zhongshan People’s Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

K2025-063-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山市人民医院临床科研与实验动物伦理委员会

Name of the ethic committee:

Ethics Committee of Clinical Research and Experimental Animals of Zhongshan Peoples Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-29 00:00:00

伦理委员会联系人:

林贤珊

Contact Name of the ethic committee:

Lin XianShan

伦理委员会联系地址:

中山市石岐区孙文东路2号

Contact Address of the ethic committee:

No.2 Sunwen East Road,Zhongshan City, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 760 89880030

伦理委员会联系人邮箱:

Contact email of the ethic committee:

249210847@qq.com

研究实施负责(组长)单位:

中山市人民医院

Primary sponsor:

Zhongshan People’s Hospital

研究实施负责(组长)单位地址:

中山市石岐区孙文东路2号

Primary sponsor's address:

No.2 Sunwen East Road,Zhongshan City, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

中山市人民医院

具体地址:

中山市石岐区孙文东路2号

Institution
hospital:

Zhongshan People’s Hospital

Address:

No.2 Sunwen East Road,Zhongshan City, Guangdong, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-raised

研究疾病:

原发性肝癌、肝硬化、肝功能衰竭  

Target disease:

Primary liver cancer, liver cirrhosis, liver failure

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

验证全腹腔镜下全肝肝移植的可行性与安全性。  

Objectives of Study:

Verifying the Feasibility and Safety of Fully Laparoscopic Total Liver Transplantation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.自愿签署知情同意书; 2.受体年龄18-65岁; 3.首次接受肝移植手术; 4.移植物来自脑死亡供体; 5.全肝肝移植; 6.基线终末期肝病模型(MELD)评分<24; 7.无重大的上腹部手术史; 8.2022年12月至2025年3月在我院进行肝移植的患者;

Inclusion criteria

1.Voluntarily sign the informed consent form;
2.Patients who underwent liver transplantation at our hospital from December 2022 to March 2025;
3.Recipient age: 18–65 years;
4.Underwent liver transplantation for the first time;
5.The transplant came from a brain-dead donor;
6.Whole Liver Transplant;
7.Baseline Model for End-Stage Liver Disease (MELD) score < 24;
8.No history of major upper abdominal surgery;

排除标准:

1.数据缺失或失访的患者;

Exclusion criteria:

1.Patients with missing data or who were not visited;

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2025-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-01 00:00:00 To 2025-06-01 00:00:00

干预措施:

Interventions:

组别:

肝移植

样本量:

50

Group:

liver transplantation

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Zhongshan People’s Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后并发症

指标类型:

主要指标

Outcome:

Postoperative complications

Type:

Primary indicator

测量时间点:

测量方法:

监测患者症状、体征及检验检查等

Measure time point of outcome:

Measure method:

Monitor patients' symptoms, signs, and laboratory tests

指标中文名:

术后肝功能

指标类型:

主要指标

Outcome:

Postoperative liver function

Type:

Primary indicator

测量时间点:

测量方法:

血液化验

Measure time point of outcome:

Measure method:

Blood test

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2027年1月1日后通过ResMan共享http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After January 1, 2027, shared via ResMan http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-22 16:10:23